scholarly journals Body mass index impacts the choice of lipid‐lowering treatment with no correlation to blood cholesterol – Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS)

2018 ◽  
Vol 20 (11) ◽  
pp. 2670-2674 ◽  
Author(s):  
Jean Ferrières ◽  
Dominik Lautsch ◽  
Anselm K. Gitt ◽  
Gaetano De Ferrari ◽  
Hermann Toplak ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
International Study ◽  
Blood Cholesterol ◽  
Lipid Lowering

Correlation Between Body Mass Index (BMI) and Fasting Total Blood Cholesterol Level among Undergraduate Students

2016 ◽  
Vol 15 (9) ◽  
pp. 873-877
Author(s):  
Saeid Reza Doustjalal ◽  
Hlaing Thaw Dar ◽  
Khin Thant Zin ◽  
Kumar Raghav Gujjar ◽  
Ratika Sharma ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Cholesterol Level ◽  
Body Mass ◽  
Undergraduate Students ◽  
Blood Cholesterol ◽  
Blood Cholesterol Level ◽  
Total Blood ◽  
Total Blood Cholesterol

scholarly journals The Efficacy of Continuous Versus Intermittent Celecoxib Treatment in Osteoarthritis Patients with Body Mass Index ≥30 and <30 kg/m2

2013 ◽  
Vol 7 (1) ◽  
pp. 32-37 ◽  
Author(s):  
George H Sands ◽  
Pritha Bhadra Brown ◽  
Margaret Noyes Essex
Keyword(s):  
Body Mass Index ◽  
Treatment Group ◽  
Body Mass ◽  
Hip Osteoarthritis ◽  
International Study ◽  
Continuous Treatment ◽  
Intermittent Treatment ◽  
Double Blind ◽  
Parallel Group ◽  
To Receive

Objective: Characterize the effect of body mass index (BMI) on the efficacy of continuous daily celecoxib treatment compared with intermittent celecoxib treatment. Methods: Prespecified exploratory analysis of a 24-week, double-blind, parallel-group, randomized, multicenter international study. 858 patients with knee or hip osteoarthritis (OA) were randomized to receive celecoxib 200 mg daily either as continuous or intermittent treatment. Efficacy was measured by Western Ontario and McMaster Universities Arthritis Index (WOMAC) total and subscale scores and the number of flare events. Results: Least squares mean increases (worsening) in WOMAC total scores were significantly less in the continuous treatment group than in the intermittent treatment group in patients with a BMI <30 kg/m2 (1.33 vs 4.85; p=0.016) and in patients with a BMI ≥30 kg/m2 (1.84 vs 5.12; p=0.019). There was a greater worsening in patients with a BMI ≥30 kg/m2 than in those with a BMI <30 kg/m2 in both the continuous and intermittent groups. Fewer flares were reported in the continuous treatment group than in the intermittent group in patients with a BMI <30 kg/m2 (0.55 vs 0.88; p<0.0001) and ≥30 kg/m2 (0.54 vs 0.97; p<0.0001). There were no differences in adverse events in the two BMI groups. Conclusions: Continuous celecoxib treatment was significantly more efficacious than intermittent use in patients with a BMI <30 kg/m2 compared with obese patients (≥30 kg/m2) as assessed by WOMAC total scores and the number of flares. These data suggest that including weight loss as part of a treatment regimen for obese OA patients could be important.

scholarly journals Association of TNF-α 308 polymorphism with diabetes mellitus type 2

2018 ◽  
Vol 59 (4) ◽  
pp. 313-316
Author(s):  
Sadeq K. Hachim
Keyword(s):  
Diabetes Mellitus ◽  
Body Mass Index ◽  
Body Mass ◽  
The Body ◽  
Blood Cholesterol ◽  
Restriction Enzyme Digestion ◽  
Healthy Controls ◽  
Current Case ◽  
Study Parameter

Back ground: The association between tumors necrosis factor-alpha (TNF-á)308 polymorphism and type 2 diabetes mellitus (T2DM) remains controversial .The variation in ethnicity and life style play important role in these conflicting results.Objective: To investigate association of TNF-á 308 polymorphism with T2DM,TNF level and body mass index in these patients.Patients and methods: The current case control study included fifty patients with T2DM in addition to twenty five healthy controls. The fasting blood sugar (FBS)and fasting blood (cholesterol, triglyceride) were done by colorimetric methods .The body mass index (BMI) was calculated for each patients and healthy controls. The level TNF-á in serum was measured by ELISA method(Ray biotechnology/ USA, 46078). The TNF-á 308 polymorphism was done by restriction enzyme digestion after polymerase chain reaction (PCR).Result: The age range for T2DM patients was (43.54±4.590) year while for control was (45.04±4.394) year. The T2DM patients whom carry AA alleles for TNF-á 308 polymorphism showed highly significant association with study parameter F.B.S, BMI, cholesterol, triglyceride and TNF-á level with (P.0.01).The T2DM patients with normal allele GG genotyping and GA genotyping of TNF-á 308 polymorphism also showed highly significant association with study parameter F.B.S,BMI,Cholesterol,Triglyecride and TNF- á with (P.0.01). The TNF- á level in serum of T2DM patients showed highly significant association with F.B.S, cholesterol and triglyceride with (P P.0.01), however the TNF- á level was nonsignificant with BMI in T2DM patients.Conclusion: In the present study TNF-á 308 polymorphism allele (AA, GA) showed a statistically significant association with TNF-á level in serum of T2DM patients and BMI. The AA and GA alleles showed a statistically significant association with high fasting glucose level. The TNF- á level didn't show a statistically significant association with BMI.  

scholarly journals Long-Term Burden of Increased Body Mass Index from Childhood on Adult Dyslipidemia: The i3C Consortium Study

2019 ◽  
Vol 8 (10) ◽  
pp. 1725 ◽  
Author(s):  
Yinkun Yan ◽  
Lydia A. Bazzano ◽  
Markus Juonala ◽  
Olli T. Raitakari ◽  
Jorma S. A. Viikari ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Early Life ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Lipid Levels ◽  
Increased Risk ◽  
The Impact

Background: Data are limited regarding the association of cumulative burden and trajectory of body mass index (BMI) from early life with adult lipid disorders. Methods: The study cohort consisted of 5195 adults who had BMI repeatedly measured 4 to 21 times from childhood and had blood lipid measurements of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) and information on lipid-lowering medications in the last adult survey. The area under the curve (AUC) was calculated as a measure of long-term burden (total AUC) and trends (incremental AUC) of BMI. Results: Participants with dyslipidemia, high LDL-C, low HDL-C and high TG had consistently and significantly higher BMI levels from childhood to adulthood compared to those with normal lipid levels. After adjusting for age, race, sex, and cohort, increased risk of adult dyslipidemia was significantly associated with higher values of childhood BMI, adulthood BMI, total AUC and incremental AUC, with odds ratio (95% confidence interval) = 1.22 (1.15–1.29), 1.85 (1.74–1.97), 1.61 (1.52–1.71), and 1.59 (1.50–1.69), respectively, and p < 0.001 for all. The association patterns were similar in most race–sex subgroups. Conclusions: Adults with dyslipidemia versus normal lipid levels have consistently higher levels and distinct life-course trajectories of BMI, suggesting that the impact of excessive body weight on dyslipidemia originates in early life.

scholarly journals The −256T>C Polymorphism in the Apolipoprotein A-II Gene Promoter Is Associated with Body Mass Index and Food Intake in the Genetics of Lipid Lowering Drugs and Diet Network Study

2007 ◽  
Vol 53 (6) ◽  
pp. 1144-1152 ◽  
Author(s):  
Dolores Corella ◽  
Donna K Arnett ◽  
Michael Y Tsai ◽  
Edmond K Kabagambe ◽  
James M Peacock ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Food Intake ◽  
Dietary Intake ◽  
Body Mass ◽  
Proton Nuclear Magnetic Resonance ◽  
Lipid Lowering ◽  
Resonance Spectroscopy ◽  
Lipid Lowering Drugs ◽  
Apolipoprotein A ◽  
Validated Questionnaire

Abstract Background: Apolipoprotein A-II (APOA2) plays an ambiguous role in lipid metabolism, obesity, and atherosclerosis. Methods: We studied the association between a functional APOA2 promoter polymorphism (−265T&gt;C) and plasma lipids (fasting and postprandial), anthropometric variables, and food intake in 514 men and 564 women who participated in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study. We obtained fasting and postprandial (after consuming a high-fat meal) measures. We measured lipoprotein particle concentrations by proton nuclear magnetic resonance spectroscopy and estimated dietary intake by use of a validated questionnaire. Results: We observed recessive effects for this polymorphism that were homogeneous by sex. Individuals homozygous for the −265C allele had statistically higher body mass index (BMI) than did carriers of the T allele. Consistently, after multivariate adjustment, the odds ratio for obesity in CC individuals compared with T allele carriers was 1.70 (95% CI 1.02–2.80, P = 0.039). Interestingly, total energy intake in CC individuals was statistically higher [mean (SE) 9371 (497) vs 8456 (413) kJ/d, P = 0.005] than in T allele carriers. Likewise, total fat and protein intakes (expressed in grams per day) were statistically higher in CC individuals (P = 0.002 and P = 0.005, respectively). After adjustment for energy, percentage of carbohydrate intake was statistically lower in CC individuals. These associations remained statistically significant even after adjustment for BMI. We found no associations with fasting lipids and only some associations with HDL subfraction distribution in the postprandial state. Conclusions: The −265T&gt;C polymorphism is consistently associated with food consumption and obesity, suggesting a new role for APOA2 in regulating dietary intake.

Abstract 10922: Relationship of the AHA Impact Goals (Life’s Simple 7) With Risk of Chronic Kidney Disease: Results From the ARIC Cohort Study

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Casey M Rebholz ◽  
Cheryl A Anderson ◽  
Morgan E Grams ◽  
Lydia A Bazzano ◽  
Deidra C Crews ◽  
...  
Keyword(s):  
Physical Activity ◽  
Blood Pressure ◽  
Body Mass Index ◽  
Blood Glucose ◽  
Body Mass ◽  
Cardiovascular Health ◽  
Blood Cholesterol ◽  
Health Factors ◽  
Life’S Simple 7 ◽  
Life's Simple 7

Introduction: As part of its 2020 Impact Goals, the AHA developed the Life’s Simple 7 metric for cardiovascular health promotion. The metric consists of ideal categories for smoking, physical activity, diet, body mass index, blood pressure, blood cholesterol, and blood glucose; and its relationship with risk of chronic kidney disease (CKD) is unknown. Hypothesis: Ideal levels of health factors and the overall Life’s Simple 7 metric are associated with lower risk of developing CKD. Methods: We prospectively analyzed 15,436 Atherosclerosis Risk in Community study participants without CKD at baseline (1987-1989). Ideal levels of health factors were: non-smoker or quit >1 year ago; body mass index <25 kg/m 2 ; ≥150 minutes/week of physical activity; dietary pattern which is high in fruits and vegetables, fish, and fiber-rich whole grains, and low in sodium and sugar-sweetened beverages; total cholesterol <200 mg/dL; blood pressure <120/90 mmHg; and blood glucose <100 mg/dL. Incident CKD was defined as development of estimated glomerular filtration rate <60 mL/min/1.73 m 2 accompanied by 25% decline from baseline, hospitalization or death due to CKD, or end-stage renal disease defined by linkage with the U.S. Renal Data System. Cox regression was used to estimate associations between health factors, the overall metric, and CKD risk while adjusting for age, sex, race, and baseline kidney function. Results: At baseline, mean age was 54 years, 55% were women, and 26% were African-American. There were 2,861 incident CKD cases over a median follow-up of 22 years. Smoking, body mass index, physical activity, blood pressure, and blood glucose were associated with lower CKD risk (all p≤0.01), but diet and blood cholesterol were not. CKD risk was inversely related to the number of ideal health factors ( Figure ; p-trend<0.001; AUC: 0.7001 vs. 0.6804, p<0.001). Conclusions: The AHA Life’s Simple 7 metric, developed to measure and promote cardiovascular health, predicts reduced CKD risk.

Does Body Mass Index Impact The Choice Of Lipid Lowering Treatment?

2016 ◽  
Vol 10 (3) ◽  
pp. 694-697
Author(s):  
Dominik Lautsch ◽  
Anselm Gitt ◽  
Jean Ferrieres ◽  
Martin Horack ◽  
Philippe Brudi ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Lipid Lowering
Sign in / Sign up

Export Citation Format

Share Document